Highest-materiality recent filing
Black Diamond reports positive Phase 2 silevertinib results; mPFS 15.2 months in EGFR-NCM NSCLC
Preliminary mPFS 15.2 months (95% CI: 10.8, NE); median DOR not reached; 53% of patients remain on therapy.
Black Diamond Therapeutics FY2025: net income $22.4M; cash $128.7M; silevertinib milestones Q2 2026
Net income of $22.4M for FY2025 vs net loss $69.7M in 2024; Q4 net loss $15.1M.
60% ORR (26/43) in 1L NSCLC with 35 distinct non-classical EGFR mutations; 86% CNS ORR in patients with brain metastases.
Black Diamond completes Phase 2 enrollment for silevertinib; net loss narrows to $10.6M
Cash $142.8M (vs $98.6M Dec 2024) funds operations into Q4 2027.
Black Diamond Therapeutics Q1 net income $56.5M on Servier deal; cash runway into Q4 2027
Net income $56.5M in Q1 2025 vs net loss $18.2M in Q1 2024, driven by $70M upfront from Servier licensing deal.
Black Diamond grants Servier worldwide license for BDTX-4933; $70M upfront, up to $710M milestones
Upfront payment of $70M; eligible for up to $710M in development/commercial milestones plus tiered royalties on global sales.
Black Diamond Therapeutics reports Q4/FY2024 net loss $16M/$69.7M; cash $98.6M into Q4 2026
Cash, cash equivalents, and investments $98.6M at Dec 31, 2024, down from $131.4M at Dec 31, 2023.
Black Diamond Therapeutics reports Q3 net loss of $15.6M; BDTX-1535 Phase 2 data
Net loss of $15.6M in Q3 2024 vs $23.0M in Q3 2023; cash and investments $112.7M, sufficient into Q2 2026.
CFO Fang Ni and CPO Elizabeth Montgomery depart; Erika Jones appointed Principal Financial Officer.
Black Diamond reports initial Phase 2 data for BDTX-1535 showing 42% ORR in recurrent EGFRm NSCLC
200 mg daily dose selected for pivotal development; favorable tolerability with no new safety signals.
Black Diamond Q2 2024 net loss $19.9M; cash runway into Q4 2025; Phase 2 data on track
Cash, equivalents, investments $123.0M at June 30, 2024, down from $131.4M at Dec 31, 2023; runway into Q4 2025.
Black Diamond Q1 net loss $18.2M; cash $115.2M; Phase 2 BDTX-1535 data on track for Q3 2024
Net loss of $18.2M for Q1 2024 vs $20.9M in Q1 2023; R&D exp $13.5M, G&A $6.7M.
Erika Jones, the Company’s Senior Vice President, Finance and Corporate Controller, and principal accounting officer, was appointed as principal financial officer of the Company.
On October 7, 2024, Black Diamond Therapeutics, Inc. (the “Company”) terminated Fang Ni, Pharm. D. without Cause (as such term is defined in his employment agreement with the Company, which was filed as Exhibit 10.12 to the Company’s Annual Report on Form 10-K filed on March 9, 2023 (the “Employment Agreement”)) as Chief Business Officer, Chief Financial Officer and principal financial officer of the Company, in each case, effective as of October 7, 2024
Wendy L. Dixon, Ph.D. resigned from the Board and all committees thereof, including her position as Chair of the Nominating and Corporate Governance Committee of the Board
the Board appointed (i) Prakash Raman, Ph.D. to serve on the Board as a Class I director
Alexander Mayweg, Ph.D. resigned from the Board of Directors (the “Board”) of Black Diamond Therapeutics, Inc. (the “Company”).
Max materiality 0.85 · Median 0.65 · Most common event earnings